--- title: "Sobetirome (GC-1): Dosing & Vendor Prices — BodyHackGuide" description: "Sobetirome (GC-1): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Sobetirome (GC-1)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Sobetirome (GC-1)", "description": "Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them.", "url": "https://www.bodyhackguide.co/compound/sobetirome", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "149.99", "highPrice": "149.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "149.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/gc-1-sobetirome/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Sobetirome (GC-1)", "description": "Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them.", "lastReviewed": "2026-09-07T04:47:47.589Z", "url": "https://www.bodyhackguide.co/compound/sobetirome", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Sobetirome (GC-1)", "alternateName": [ "GC-1", "QRX-431", "Sobetiroma", "NV1205", "thyromimetic GC-1" ], "description": "Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them.", "activeIngredient": "Sobetirome (GC-1)", "administrationRoute": "Oral", "mechanismOfAction": "Sobetirome is a selective agonist of thyroid hormone receptor beta (TR-beta) over TR-alpha. TR-beta predominates in liver and mediates the cholesterol-lowering and lipid effects of thyroid hormone, while TR-alpha predominates in heart and mediates chronotropic and inotropic effects, so subtype selectivity plus preferential liver accumulation separates lipid lowering from tachycardia (PMID: 10965874; PMID: 19002578). Activated TR-beta increases hepatic LDL receptor expression and cholesterol disposal, stimulates steps of reverse cholesterol transport in mice (PMID: 16006512), and increases whole-body oxygen consumption in rats to a degree comparable with triiodothyronine while sparing skeletal muscle mass (PMID: 17400799). The same receptor mediates a proliferative response in rat hepatocytes and pancreatic acinar cells (PMID: 16574785).", "dosageForm": "liquid", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Sobetirome (GC-1) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them." } }, { "@type": "Question", "name": "What forms does Sobetirome (GC-1) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Sobetirome (GC-1) is available in liquid form." } }, { "@type": "Question", "name": "How much does Sobetirome (GC-1) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $149.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Sobetirome (GC-1) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fsobetirome) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Sobetirome (GC-1) [Where to buy Sobetirome (GC-1)](/buy/sobetirome) [Sobetirome (GC-1) coupon codes](/coupons/sobetirome) [Sobetirome (GC-1) protocol](/protocol/sobetirome) [Alternatives to Sobetirome (GC-1)](/alternatives-to/sobetirome) [Sobetirome (GC-1) side effects](/side-effects/sobetirome) 1. [Home](/) 3. [Compounds](/compare) 5. Sobetirome (GC-1) ![Sobetirome (GC-1) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Sobetirome (GC-1) Metabolic Discontinued Download PDF Also known as: GC-1, QRX-431, Sobetiroma, NV1205, thyromimetic GC-1 Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. Half-Life: Not established in humans; no peer-reviewed human pharmacokinetic study has been published, and the phase 1 program results were not reported in the peer-reviewed literature (PMID: 19002578) Route: Oral MW: 328.40 g/mol CAS: 211110-63-3 Last reviewed: Sep 7, 2026 [ Metabolic Category ](/wiki#cat-metabolic) Discontinued Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $149.99 30 mL liquid or 60 capsules (price varies by presentation) · liquid [Buy Now](https://disguisedalpha.com/product/gc-1-sobetirome/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Sobetirome is a selective agonist of thyroid hormone receptor beta (TR-beta) over TR-alpha. TR-beta predominates in liver and mediates the cholesterol-lowering and lipid effects of thyroid hormone, while TR-alpha predominates in heart and mediates chronotropic and inotropic effec… Half-Life Not established in humans; no peer-reviewed human pharmacokinetic study has been published, and the phase 1 program results were not reported in the peer-reviewed literature (PMID: 19002578) Routes Oral Potential Benefits Lowered cholesterol about 30 times more potently than it caused tachycardia in cholesterol-fed rats (PMID: 14701670) Lowered cholesterol and lipoprotein(a) with no tachycardia and about 4 percent body weight reduction in cynomolgus monkeys (PMID: 14701670) Increased oxygen consumption 50 to 70 percent and prevented fat mass accumulation over six weeks in rats, with far less skeletal muscle loss than triiodothyronine (PMID: 17400799) Lowered triglycerides more than triiodothyronine without raising heart rate in hypothyroid mice (PMID: 10965874) Reduced serum lipids and stimulated steps of reverse cholesterol transport in euthyroid mice (PMID: 16006512) ### Overview Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them. ### Potential Research Fields Thyroid hormone receptor beta Lipid lowering Energy expenditure Demyelinating disease ## Chemical Information IUPAC Name Not yet available CAS Number 211110-63-3 Molecular Formula C20H24O4 Molecular Mass 328.40 g/mol ![Sobetirome (GC-1) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/9862248/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/9862248) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Mechanism-based, since no human trial has defined contraindications. Thyroid hormone receptor agonism is inappropriate for anyone with existing hyperthyroidism, atrial fibrillation or unstable coronary disease, and it suppresses thyroid stimulating hormone and disturbs thyroid function testing (PMID: 10965874). The rat liver and pancreas proliferation findings argue against use by anyone with liver disease or pancreatic disease (PMID: 16574785). No human pregnancy, lactation or pediatric data exist. Anyone taking levothyroxine or antithyroid medication would have their treatment monitoring confounded. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $149.99 Best $/mg — Vendors 1 Listings 1 liquid [Sign in for alerts ](/auth) Form Allliquid Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK GC-1 (Sobetirome) liquid 30 mL liquid or 60 capsules (price varies by presentation) ● In Stock $149.99 BEST — — [Buy](https://disguisedalpha.com/product/gc-1-sobetirome/?coupon=reddit) Get Sobetirome (GC-1) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $149.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Sobetirome (GC-1). [Sign in](/auth) Current low $149.99 as of Sep 7, 2026 7-day low $149.99 30-day low $149.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Sobetirome (GC-1) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $149.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### AICAR (acadesine) Metabolic Phase 3 AICAR is a nucleoside analog of adenosine. t½ Intact acadesine was measurable in plasma for only about 2 hours after a short intravenous infusion in four healthy men, with total plasma clearance of 2.2 L/h/kg and negligible protein binding; radiolabeled drug-derived material had an apparent terminal half-life of about one week, reflecting metabolites rather than parent compound (PMID: 8227467) Preclinical View Profile ](/compound/aicar)[ ### Amlexanox Metabolic FDA Approved Amlexanox is an old anti-inflammatory drug with a second life. t½ Not established in published human pharmacokinetic studies for the oral capsule form; a validated plasma assay has been used for preclinical pharmacokinetics in rats (PMID: 34842293) Preclinical View Profile ](/compound/amlexanox)[ ### Berberine Metabolic Preclinical Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi). Preclinical View Profile ](/compound/berberine)[ ### Cardarine (GW501516) Metabolic Discontinued Cardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome. t½ Not reported in the published human trials; the phase 1 and phase 2 studies described lipid outcomes over two to twelve weeks of oral dosing without publishing a terminal half-life (PMID: 17110604; PMID: 22814748) Preclinical View Profile ](/compound/cardarine)[ ### Metformin Metabolic Preclinical Metformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually. Preclinical View Profile ](/compound/metformin)[ ### SLU-PP-915 Metabolic Preclinical SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. t½ Not established in humans; in mice it is orally bioavailable and active by both oral and intraperitoneal routes, unlike its predecessor SLU-PP-332 (PMID: 41421047) Preclinical View Profile ](/compound/slu-pp-915) [ View Full Dosage Guide → Protocols, calculator & safety for Sobetirome (GC-1) ](/guides/dosage/sobetirome) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $149.99 [Buy Now](https://disguisedalpha.com/product/gc-1-sobetirome/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established in humans; no peer-reviewed human pharmacokinetic study has been published, and the phase 1 program results were not reported in the peer-reviewed literature (PMID: 19002578) Molecular Weight 328.40 g/mol Administration Oral CAS Number 211110-63-3 Trial Phase Discontinued 0 [Full Dosage Guide](/guides/dosage/sobetirome)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Sobetirome (GC-1) used for in research? Sobetirome, also called GC-1 and later QRX-431, is a synthetic analog of thyroid hormone made in Thomas Scanlan laboratory and first described in 1998 as a high-affinity, subtype-selective agonist for the thyroid hormone receptor (PMID: 9653548). The idea behind it is straightforward: thyroid hormone lowers cholesterol and raises metabolic rate, but it also speeds the heart, and the receptor that drives the heart effects is a different subtype from the one that drives the liver effects. A drug selective for the beta subtype should separate the two. QuatRx Pharmaceuticals developed it as a cholesterol-lowering agent and the program was later reviewed as a case history in drug discovery (PMID: 19002578). The animal data support the separation. In hypothyroid mice and hypercholesteremic rats, GC-1 lowered triglycerides better than triiodothyronine and lowered cholesterol comparably, but did not raise heart rate or normalize the cardiac genes that thyroid hormone acts on (PMID: 10965874). In cholesterol-fed rats it lowered cholesterol at roughly 30 times lower exposure than needed to cause a fast heart rate, and in cynomolgus monkeys it lowered cholesterol and lipoprotein(a) with no tachycardia and about a 4 percent reduction in body weight (PMID: 14701670). In euthyroid mice it reduced serum lipids and stimulated steps of reverse cholesterol transport (PMID: 16006512). For body composition, the relevant rat study ran six weeks and compared GC-1 with triiodothyronine at matched doses. Oxygen consumption rose 50 to 70 percent with both. Control rats gained about 80 percent more fat mass, triiodothyronine-treated rats lost 70 to 90 percent, and GC-1-treated rats lost about 20 percent. The difference that matters is muscle: triiodothyronine shrank individual skeletal muscles while GC-1 barely did, and GC-1 did not drive up food intake the way triiodothyronine did (PMID: 17400799). There is a safety signal that gets left out of marketing. In rats, GC-1 was a strong mitogen: it stimulated hepatocyte proliferation without tissue injury and induced massive pancreatic acinar cell proliferation (PMID: 16574785). That is a proliferation finding in two organs, in a compound intended for chronic use. Human evidence is thin. Phase 1 single-dose and two-week multiple-dose studies in healthy volunteers were announced by the sponsor as showing LDL cholesterol reductions, but those results were reported in company announcements rather than a peer-reviewed trial publication, and the cholesterol program did not continue. Sobetirome was later picked up for X-linked adrenoleukodystrophy, but both registered trials, NCT01787578 and NCT03196765, were withdrawn without enrolling a single participant. More recent work has focused on the brain-penetrant prodrug Sob-AM2 in animal models of demyelination (PMID: 29845892; PMID: 36792926). Capsules sold as sobetirome are an unapproved thyroid-active drug with no completed human trial behind them. What forms does Sobetirome (GC-1) come in? Sobetirome (GC-1) is available in liquid form. How much does Sobetirome (GC-1) cost? Prices start at $149.99 across 1 verified vendor. How do I compare Sobetirome (GC-1) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### AICAR (acadesine) Metabolic Phase 3 AICAR is a nucleoside analog of adenosine. t½ Intact acadesine was measurable in plasma for only about 2 hours after a short intravenous infusion in four healthy men, with total plasma clearance of 2.2 L/h/kg and negligible protein binding; radiolabeled drug-derived material had an apparent terminal half-life of about one week, reflecting metabolites rather than parent compound (PMID: 8227467) Preclinical View Profile ](/compound/aicar)[ ### Amlexanox Metabolic FDA Approved Amlexanox is an old anti-inflammatory drug with a second life. t½ Not established in published human pharmacokinetic studies for the oral capsule form; a validated plasma assay has been used for preclinical pharmacokinetics in rats (PMID: 34842293) Preclinical View Profile ](/compound/amlexanox)[ ### Berberine Metabolic Preclinical Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi). Preclinical View Profile ](/compound/berberine)[ ### Cardarine (GW501516) Metabolic Discontinued Cardarine is the market name for GW501516, a synthetic agonist of the nuclear receptor PPAR-delta developed by GlaxoSmithKline as a treatment for low HDL cholesterol and the lipid problems that travel with metabolic syndrome. t½ Not reported in the published human trials; the phase 1 and phase 2 studies described lipid outcomes over two to twelve weeks of oral dosing without publishing a terminal half-life (PMID: 17110604; PMID: 22814748) Preclinical View Profile ](/compound/cardarine)[ ### Metformin Metabolic Preclinical Metformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually. Preclinical View Profile ](/compound/metformin)[ ### SLU-PP-915 Metabolic Preclinical SLU-PP-915 is an experimental agonist of the estrogen-related receptors, a family of three orphan nuclear receptors called ERR-alpha, ERR-beta and ERR-gamma that control genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. t½ Not established in humans; in mice it is orally bioavailable and active by both oral and intraperitoneal routes, unlike its predecessor SLU-PP-332 (PMID: 41421047) Preclinical View Profile ](/compound/slu-pp-915) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-sobetirome) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋